Clinical Trial Update: Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of intramural DTI-015 for recurrent malignant gliomas has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Glioma

Drugs mentioned

• DTI-015

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Glioma, Brain Neoplasms | Phase 1, Phase 2 | Status: COMPLETED